Sabarubicin (SABA) in combination with cisplatin (DDP): Maximum tolerated dose (MTD) evaluation (phase I step) followed by a phase II step in patients (pts) with small cell lung cancer-extensive disease (SCLC-ED).

Abstract

7048 Background: SABA, a 3rd generation anthracycline with promising activity as single agent in solid tumors was evaluated to establish the MTD in combination with DDP (phase I), followed by a pha...